CALC — CalciMedica, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1534133 ·
Last close
$0.76
Market Cap
$12.01M
52W High
$0.93
52W Low
$0.46
ADV30
137,514
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,611,000 | 4,976,000 | 8,609,000 | 8,164,000 | 9,713,000 |
| Dec 2025 | 0 | — | -4,385,000 | -10,760,000 | 13,591,000 | 11,520,000 | 20,232,000 |
| Sep 2025 | 0 | — | -5,618,000 | -7,804,000 | 14,913,000 | 5,470,000 | 15,181,000 |
| Jun 2025 | 0 | — | -6,621,000 | -5,956,000 | 19,080,000 | 5,918,000 | 12,977,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,178,000
Investing CF
$9,551,000
Financing CF
$15,212,000
CapEx
$-28,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.78
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-189,326,000
Inventory
—
Receivables
—
ST Investments
$1,496,000
EBIT TTM
$-28,140,000
Pretax Income TTM
$-29,562,000
Interest Exp TTM
$1,422,000
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -23,121,000 | -29,562,000 | 13,591,000 | 20,232,000 | — | -21,178,000 |
| Dec 2024 | 0 | -24,204,000 | -13,700,000 | 19,794,000 | 5,384,000 | — | -21,146,000 |
| Dec 2023 | 0 | -38,075,000 | -34,357,000 | 12,185,000 | 4,028,000 | — | -25,730,000 |
| Dec 2022 | 0 | -14,193,000 | -7,824,000 | 3,349,000 | 12,582,000 | — | -11,757,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KPRX | KIORA PHARMACEUTICALS INC | $11.97M | $2.70 | — |
| PRNAF | ALTERITY THERAPEUTICS LTD | $11.96M | $0.00 | — |
| GOVX | GeoVax Labs, Inc. | $12.12M | $3.49 | — |
| PHIO | Phio Pharmaceuticals Corp. | $12.55M | $1.08 | — |
| APRE | Aprea Therapeutics, Inc. | $11.27M | $0.91 | — |
News headlines (Yahoo Finance, 1h cache)
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
2026-05-12 11:00 · Yahoo
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
2026-03-03 12:00 · Yahoo
CalciMedica’s stock drops 75% on acute kidney injury trial termination
2026-01-29 12:24 · Yahoo
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
2026-01-28 12:00 · Yahoo
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
2025-11-12 12:01 · Yahoo
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
2025-11-12 12:00 · Yahoo
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
2025-11-10 12:00 · Yahoo
CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
2025-10-14 11:00 · Yahoo
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
2025-09-02 11:00 · Yahoo
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
2025-08-12 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.